欧州の全ゲノムおよびエクソームシーケンシング市場：エンドユーザー・国別の分析・予測 (2024-2033年)

欧州の全ゲノムおよびエクソームシーケンシングの市場規模は、2024年の5億4,900万米ドルから、予測期間中は13.94%のCAGRで推移し、2033年には17億7,730万米ドルに達すると予測されています。

エクソームシーケンシング (WES) と全ゲノムシーケンシング (WGS) は、欧州の遺伝子解析に革命をもたらしている最先端のゲノム技術です。WGSはコード領域と非コード領域を含むゲノム全体を解読するのに対し、WESは疾患関連変異の大部分を含むタンパク質をコードするエクソンのみを対象とします。これらの技術は、臨床診断、個別化医療、希少疾患研究に革命をもたらし、医療の革新を後押ししています。技術が進歩し続け、コストが下がり、その応用が拡大する中で、WGSとWESは欧州のゲノミクスにおいて不可欠なツールになりつつあります。

欧州の全ゲノムおよびエクソームシーケンシング市場は、個別化医療への需要の高まり、臨床診断の採用拡大、ゲノム研究の向上により大きく拡大しています。エクソームシーケンシング (WES) は、既知の疾患関連変異の大部分が存在するタンパク質コード領域に集中するのに対し、全ゲノムシーケンシング (WGS) は人の完全な遺伝子構成を徹底的に調べることができます。疾患の早期発見、精密治療、遺伝子疾患に対するより深い理解を促進することで、これらの技術は医療業界に変革をもたらしつつあります。

WGSおよびWESのニーズは、特に臨床および研究環境における癌、神経疾患、希少疾患の発生率の上昇により高まっています。市場の拡大は、ゲノム医療に対する政府の資金援助やイニシアチブ、バイオテクノロジー企業と医療機関の提携によっても後押しされています。さらに、シーケンシング技術の継続的な向上によりコストが削減され、これらの高度なツールがより利用しやすくなっています。

データの正確性と患者の安全性を保証する厳格な規制の枠組みにより、欧州はゲノム革新の最前線にあります。腫瘍、感染症研究、生殖医療における用途の拡大も市場成長に寄与しています。ゲノムシーケンシングが進化を続ける中、欧州全域で精密医療と生物医学研究の将来において重要な役割を果たすことになるでしょう。

市場の分類

セグメンテーション1：エンドユーザー別

• 製薬・バイオテクノロジー企業
• 診断ラボ
• 病院・クリニック
• 研究・学術機関
• その他

セグメンテーション2：地域別

• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • オランダ
  • その他

当レポートでは、欧州の全ゲノムおよびエクソームシーケンシングの市場を調査し、主要動向、市場影響因子の分析、法規制環境、市場規模の推移・予測、各種区分・主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

範囲と定義

第1章 業界の展望

• 市場動向
  • シーケンシング技術における技術革新
  • 市場における数多くの無機的成長活動
• COVID-19別市場への影響
• 規制の枠組み
  • 欧州における法的要件と枠組み
• サプライチェーン分析
• 市場力学の概要
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第2章 地域

• 地域別概要
• 欧州
  • 地域概要
  • 市場成長の原動力
  • 市場課題
  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • オランダ
  • その他

第3章 市場：競合ベンチマーキングと企業プロファイル

• 主要戦略・展開
• 企業シェア分析
• 企業プロファイル
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Oxford Nanopore Technologies plc
  • QIAGEN N.V.

第4章 調査手法

List of Figures

• Figure 1: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023, 2026, and 2033
• Figure 2: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023, 2026, and 2033
• Figure 3: Key Events to Keep Track of within the Whole Genome and Exome Sequencing Market
• Figure 4: Value and Supply Chain Analysis, Whole Genome and Exome Sequencing Market
• Figure 5: Analysis of Market Navigating Factors, 2023-2033
• Figure 6: Key Clinical Applications of Whole Genome and Whole Exome Sequencing
• Figure 7: Number of Research Papers Mentioning Personalized Medicine in PubMed, 2010-2023
• Figure 8: Decreasing Genome Sequencing Costs
• Figure 9: Map of a Few Recent and Ongoing Government-Funded National Genomic-Medicine Initiatives
• Figure 10: Examples of Security Breaches in Whole Genome and Exome Sequencing
• Figure 11: France Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 12: Germany Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 13: U.K. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 14: Spain Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 15: Italy Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 16: Netherlands Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 17: Rest-of-Europe Whole Genome and Exome Sequencing Market, $Million, 2023-2033
• Figure 18: Strategic Initiatives, January 2021-April 2024
• Figure 19: Share of Strategic Initiatives, January 2021-April 2024
• Figure 20: Whole Genome and Exome Sequencing Market, Company Revenue Share Analysis, 2023
• Figure 21: Data Triangulation
• Figure 22: Top-Down and Bottom-Up Approach
• Figure 23: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: Recent Technological Innovations
• Table 4: Few Major Inorganic Growth Activities in the Whole Genome and Exome Sequencing Market
• Table 5: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023-2033
• Table 6: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033

Introduction to Europe Whole Genome and Exome Sequencing Market

The Europe whole genome and exome sequencing market is projected to reach $1,777.3 million by 2033 from $549.0 million in 2024, growing at a CAGR of 13.94% during the forecast period 2024-2033. Exome sequencing (WES) and whole genome sequencing (WGS) are cutting-edge genomic technologies that are revolutionising genetic analysis in Europe. WGS decodes the entire genome, including coding and non-coding regions, while WES only targets protein-coding exons, which contain the majority of disease-related variants. These techniques are boosting healthcare innovation by revolutionising clinical diagnostics, personalised medicine, and rare disease research. As technology continues to advance, costs come down, and their applications expand, WGS and WES are becoming indispensable tools in European genomics.

Market Introduction

The market for whole genome and exome sequencing in Europe is expanding significantly due to the growing demand for personalised medicine, growing adoption of clinical diagnostics, and improvements in genomic research. Exome sequencing (WES) concentrates on protein-coding regions, which are home to the majority of known disease-related variants, whereas whole genome sequencing (WGS) offers a thorough examination of a person's complete genetic composition. By facilitating early disease detection, precision treatment, and a better understanding of genetic disorders, these technologies are transforming the healthcare industry.

The need for WGS and WES has increased due to the rising incidence of cancer, neurological disorders, and rare diseases, especially in clinical and research settings. Market expansion is also being aided by government funding and initiatives for genomic medicine, as well as partnerships between biotech companies and healthcare organizations. Additionally, ongoing improvements in sequencing technology are reducing costs, making these advanced tools more accessible.

With stringent regulatory frameworks ensuring data accuracy and patient safety, Europe is at the forefront of genomic innovation. Expanding applications in oncology, infectious disease research, and reproductive health are also contributing to market growth. As genomic sequencing continues to evolve, it is set to play a crucial role in the future of precision medicine and biomedical research across Europe.

Market Segmentation

Segmentation 1: by End User

• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Hospitals and Clinics
• Research and Academic Institutes
• Others

Segmentation 2: by Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies plc
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Industry Outlook

• 1.1 Market Trends
  • 1.1.1 Technological Innovations in the Sequencing Technology
  • 1.1.2 Numerous Inorganic Growth Activities in the Market
• 1.2 COVID-19 Impact on Market
• 1.3 Regulatory Framework
  • 1.3.1 Legal Requirements and Framework in Europe
• 1.4 Supply Chain Analysis
• 1.5 Market Dynamics Overview
  • 1.5.1 Market Drivers
    • 1.5.1.1 Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics
    • 1.5.1.2 Rising Demand for Personalized Medicine Influencing the Demand for Whole Genome and Exome Sequencing
    • 1.5.1.3 Lowering Costs and Increasing Accessibility of Genome Sequencing
    • 1.5.1.4 Ongoing Whole Genome Sequencing Government Initiatives around the World
  • 1.5.2 Market Restraints
    • 1.5.2.1 Privacy and Ethical Concerns due to Increased Risk of Security Breaches
  • 1.5.3 Market Opportunities
    • 1.5.3.1 Increasing Usage of Sequencing Technology in Emerging Markets

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
    • 2.2.3.1 By End User
  • 2.2.4 France
  • 2.2.5 Germany
  • 2.2.6 U.K.
  • 2.2.7 Spain
  • 2.2.8 Italy
  • 2.2.9 Netherlands
  • 2.2.10 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Key Strategies and Development
• 3.2 Company Share Analysis
• 3.3 Company Profiles
  • 3.3.1 Eurofins Scientific SE
    • 3.3.1.1 Overview
    • 3.3.1.2 Top Products
    • 3.3.1.3 Top Competitors
    • 3.3.1.4 Key Personnel
    • 3.3.1.5 Analyst View
  • 3.3.2 F. Hoffmann-La Roche Ltd
    • 3.3.2.1 Overview
    • 3.3.2.2 Top Products
    • 3.3.2.3 Top Competitors
    • 3.3.2.4 Key Personnel
    • 3.3.2.5 Analyst View
  • 3.3.3 Oxford Nanopore Technologies plc
    • 3.3.3.1 Overview
    • 3.3.3.2 Top Products
    • 3.3.3.3 Top Competitors
    • 3.3.3.4 Key Personnel
    • 3.3.3.5 Analyst View
  • 3.3.4 QIAGEN N.V.
    • 3.3.4.1 Overview
    • 3.3.4.2 Top Products
    • 3.3.4.3 Top Competitors
    • 3.3.4.4 Key Personnel
    • 3.3.4.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast